Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer’s disease: A systematic review and meta-analysis

The efficacy and safety of lecanemab and donanemab varied across patient subgroups, including age, sex, race/ethnicity and genetic factors such as ApoE4 genotype status. The risk of ARIA was higher in ApoE4 carriers, particularly the homozygous.